Chinese Innovative Drug Developers Report Breakthrough FDA Clinical Progress, Signaling a Golden Era for Global Expansion

　　【Pharmaceutical Network Industry DynamicsAt the beginning of 2026, there has been a wave of good news in the overseas market for innovative drugs produced in China. Multiple pharmaceutical companies have disclosed the progress of clinical trials in the U.S. Food and Drug Administration (FDA) for their innovative drugs, covering various fields such as oncology, metabolic diseases, and ophthalmic genetic disorders. Institutions point out that as more projects enter the overseas clinical validation and commercialization revenue-sharing phase, the long-term investment logic for innovative drugs continues to strengthen, with Chinese innovative drugs accelerating their integration into the global market competition landscape.
 

Among them, D3 BIO announced on January 19 that the U.S. Food and Drug Administration (FDA) had approved two of its Investigational New Drug (IND) applications. After receiving FDA IND approval, D3 BIO will advance D3S-003 (elisrasib) into a Phase I first-in-human study in patients with advanced solid tumors carrying the KRAS G12D mutation. The approved Phase II study will evaluate the combination of D3S-001 and D3S-002 in non-small cell lung cancer (NSCLC) patients with the KRAS G12C mutation who have previously been treated with a KRAS G12C inhibitor and experienced disease progression. The trial is expected to commence in the first half of 2026.
 

Data shows that Elisrasib is a new-generation KRASG12C inhibitor designed to achieve rapid, full, and selective target binding. The drug forms a covalent bond with the GDP-bound (OFF) conformation of KRASG12C, effectively blocking the nucleotide cycle and inhibiting oncogenic signaling pathways. Preclinical studies have demonstrated its potent activity, achieving complete KRASG12C target occupancy at clinically relevant exposure levels, along with central nervous system (CNS) penetration capability. Elisrasib is currently undergoing Phase II monotherapy and combination therapy studies globally, covering KRASG12C-mutated solid tumors (including NSCLC, colorectal cancer (CRC), etc.).
 

Huadong Medicine announced on January 14 that its controlling subsidiary, Zhejiang Doer Biologics Co., Ltd., received a notification from the U.S. FDA, stating that the clinical trial application for DR10624 Injection submitted by Doer Biologics has been approved by the U.S. FDA. Clinical trials can now be conducted in the United States for the indication of Metabolic Associated Steatotic Liver Disease (MASLD).
 

DR10624 is a long-acting trispecific agonist independently developed by Doer Biologics, targeting FGF21R, GCGR, and GLP-1R. The drug has successfully completed Phase II clinical research for severe hypertriglyceridemia and obtained positive topline results.
 

On January 14, Laekna Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118. LAE118 is a novel PI3Kα pan-mutation selective inhibitor intended for the treatment of patients with PIK3CA-mutated solid tumors.
 

China Resources Double-Crane announced on January 13 that DC6001 tablets, developed by its wholly-owned subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd., have received the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This marks that the innovative drug targeting Stargardt disease (a hereditary juvenile macular degeneration condition) is now officially qualified to conduct clinical trials in the United States. Data shows that Stargardt disease is a hereditary juvenile macular degeneration condition that leads to progressive loss of central vision, with severe cases potentially resulting in legal blindness. Currently, there is no effective treatment available globally, indicating an urgent clinical need. As an innovative drug focusing on this critical disease area, the advancement of DC6001 tablets holds the potential to offer new therapeutic options for patients.
 

In addition, GEB-101, a new gene-editing therapeutic drug for hereditary corneal dystrophy, has recently received approval from the U.S. Food and Drug Administration (FDA) for a new drug clinical trial (IND). GEB-101 is an in vivo genome editing therapy based on ribonucleoprotein, characterized by being "ready-to-use and rapidly degradable." It targets the root cause of the disease, achieving highly efficient targeted editing while pursuing a lower risk of off-target effects.
 

The intensive progress since the beginning of the year is the result of the accumulation of strength in China-produced innovative drugs. Data shows that China’s pipeline of new drugs under development already accounts for 30% of the global total, with the total amount of overseas licensing transactions for innovative drugs surpassing $130 billion by 2025, reaching a new high. Looking ahead to 2026, China-produced innovative drugs going global are expected to maintain a high growth momentum. Industry insiders predict that more China-produced innovative drugs will enter key clinical stages overseas this year, and the scale of overseas licensing transactions will continue to expand. Driven by policy support and increased R&D investment from companies, China's innovative drug sector is competing more vigorously in the global market, bringing more innovative therapies to patients while building a core competitiveness for high-quality industrial development.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.